Vax-induced antibodies may be less effective against new Covid variants

Neutralizing antibodies induced by the Pfizer and Moderna Covid-19 vaccines were significantly less effective against Brazil and South Africa variants, researchers say

Pfizer Vaccine, Coronavirus vaccine
Photo: Shutterstock
IANS New York
2 min read Last Updated : Mar 13 2021 | 4:44 PM IST

Neutralizing antibodies induced by the Pfizer and Moderna Covid-19 vaccines were significantly less effective against the SARS-CoV-2 variants first described in Brazil/Japan and South Africa, say researchers.

The team used their experience measuring HIV neutralizing antibodies to create similar assays for Covid-19, comparing how well the antibodies worked against the original strain versus the new variants.

"We were able to leverage the unique high-throughput capacity that was already in place and apply it to SARS-CoV-2," said researcher Alejandro Balazs from Massachusetts General Hospital in the US.

"When we tested these new strains against vaccine-induced neutralizing antibodies, we found that the three new strains first described in South Africa were 20-40 times more resistant to neutralization, and the two strains first described in Brazil and Japan were five to seven times more resistant, compared to the original SARS-CoV-2 virus," Balazs added.

According to the study, published in the journal Cells, neutralizing antibodies work by binding tightly to the virus and blocking it from entering cells, thus preventing infection.

Like a key in a lock, this binding only happens when the antibody's shape and the virus's shape are perfectly matched to each other, the researcher said.

If the shape of the virus changes where the antibody attaches to it -- in this case, in SARS-CoV-2's spike protein -- then the antibody may no longer be able to recognize and neutralize the virus as well. The virus would then be described as resistant to neutralization, they added.

Currently, all approved Covid-19 vaccines work by teaching the body to produce an immune response, including antibodies, against the SARS-CoV-2 spike protein. While the ability of these variants to resist neutralizing antibodies is concerning, it doesn't mean the vaccines won't be effective.

"The body has other methods of immune protection besides antibodies," said Balazs.

"Our findings don't necessarily mean that vaccines won't prevent Covid, only that the antibody portion of the immune response may have trouble recognizing some of these new variants," Balazs added.

--IANS

vc/sdr/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Mar 13 2021 | 4:41 PM IST

Next Story